Haisco Pharmaceutical Group Co. Ltd. has entered into an exclusive licensing agreement with Abbvie Inc., granting Abbvie the exclusive rights to develop, manufacture and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong and Macau.

The U.S. FDA issued new guidance for the development of non-opioid analgesics for chronic pain indications, with specific details on trial design, patient populations and meaningful outcomes, including reducing the nation’s reliance on opioids.

Researchers from New York University and affiliated organizations have detailed data for C-2230, a Cav2.2 channel blocker being developed for the treatment of pain.

Researchers from Gazi University and Friedrich-Schiller-Universität Jena presented the discovery and preclinical characterization of novel microsomal prostaglandin E2 synthase 1 (mPGES-1) inhibitors as potential anti-inflammatory and analgesic drug candidates.

Researchers from Indiana University have presented data from a study that aimed to assess the potential of suppressing GABA metabolism through inhibition of its degradation enzyme, GABA aminotransferase (GABA-AT), as novel analgesic strategy. The effect of next-generation GABA-AT inhibitor OV-329 was assessed in C57BL/6J mice that were intraperitoneally injected with paclitaxel to generate neuropathic nociception. Treatment with OV-329 attenuated the development and maintenance of paclitaxel-induced mechanical hypersensitivity.